company background image
GILD34

Gilead Sciences BOVESPA:GILD34 Stock Report

Last Price

R$216.04

Market Cap

R$544.2b

7D

-1.8%

1Y

17.2%

Updated

19 Jan, 2023

Data

Company Financials +

Gilead Sciences, Inc.

BOVESPA:GILD34 Stock Report

Mkt Cap: R$544.2b

GILD34 Stock Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GILD34 fundamental analysis
Snowflake Score
Valuation1/6
Future Growth3/6
Past Performance0/6
Financial Health3/6
Dividends2/6

My Notes

New

Notes are coming soon

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share PriceUS$216.04
52 Week HighUS$235.55
52 Week LowUS$132.24
Beta0.43
1 Month Change-1.28%
3 Month Change23.57%
1 Year Change17.23%
3 Year Change62.64%
5 Year Change67.52%
Change since IPO19.49%

Recent News & Updates

Recent updates

Shareholder Returns

GILD34BR BiotechsBR Market
7D-1.8%0.6%0.2%
1Y17.2%-0.2%-9.1%

Return vs Industry: GILD34 exceeded the BR Biotechs industry which returned -0.8% over the past year.

Return vs Market: GILD34 exceeded the BR Market which returned -8.5% over the past year.

Price Volatility

Is GILD34's price volatile compared to industry and market?
GILD34 volatility
GILD34 Average Weekly Movement6.2%
Biotechs Industry Average Movement9.9%
Market Average Movement6.6%
10% most volatile stocks in BR Market10.4%
10% least volatile stocks in BR Market3.2%

Stable Share Price: GILD34 is not significantly more volatile than the rest of BR stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: GILD34's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198714,400Dan O'Dayhttps://www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GILD34 fundamental statistics
Market CapR$544.21b
Earnings (TTM)R$17.28b
Revenue (TTM)R$140.61b

31.5x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GILD34 income statement (TTM)
RevenueUS$27.14b
Cost of RevenueUS$5.64b
Gross ProfitUS$21.50b
Other ExpensesUS$18.16b
EarningsUS$3.33b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.66
Gross Margin79.22%
Net Profit Margin12.29%
Debt/Equity Ratio119.8%

How did GILD34 perform over the long term?

See historical performance and comparison

Dividends

3.5%

Current Dividend Yield

109%

Payout Ratio